Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAP-2 study of trastuzumab and pertuzumab added to neoadjuvant chemoradiation for resectable HER2-positive esophageal or gastroesophageal junction adenocarcinoma
2024-513797-22-00Phase 3Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pertuzumab and trastuzumab in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: overall survival. Planned start Mar 2022; status: authorised.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-513797-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513797-22-00.